hepatitis C

Gilead Has Another Ace Up Its Sleeve
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha
Gilead Sciences
hepatitis C
Vosevi
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
Endpoints
Gilead Sciences
FDA
hepatitis C
Vosevi
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
Regulus reports a trio of pipeline setbacks
Regulus reports a trio of pipeline setbacks
BioPharma Dive
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
3 Things to Watch With Gilead Sciences, Inc. Q1 Results
3 Things to Watch With Gilead Sciences, Inc. Q1 Results
Motley Fool
Gilead Sciences
earnings
hepatitis C
Genvoya
R&D
Flag link:
Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus
Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus
Marketwatch
Bristol-Myers Squibb
China
hepatitis C
Daklinza
Flag link:
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
Endpoints
AbbVie
Enanta
hepatitis C
glecaprevir/pibrentasvir
Flag link:
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
BioPharma Dive
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead Hep C Drugs Get Supplemental FDA Nod
Gilead Hep C Drugs Get Supplemental FDA Nod
Investopedia
Gilead Sciences
hepatitis C
FDA
Harvoni
Sovaldi
Flag link:
The Worst-Case Scenario for Gilead Sciences, Inc.
The Worst-Case Scenario for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
M&A
hepatitis C
HIV
Flag link:
Should the US government license hep C drugs?
Should the US government license hep C drugs?
BioPharma Dive
hepatitis C
Merck
Gilead Sciences
Flag link:
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Fierce Pharma
Gilead Sciences
Harvoni
drug ads
DTC ads
hepatitis C
Flag link:
Gilead hepatitis C drug patent faces European challenge
Gilead hepatitis C drug patent faces European challenge
Yahoo/Reuters
Gilead Sciences
hepatitis C
Europe
sofosbuvir
Flag link:
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
Yahoo/GuruFocus
AbbVie
hepatitis C
Japan
glecaprevir/pibrentasvir
Flag link:
What Does Gilead Need? Stable HCV Scripts and “a String of Pearls”
What Does Gilead Need? Stable HCV Scripts and “a String of Pearls”
Barron's
Gilead Sciences
hepatitis C
Flag link:
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
HIV
hepatitis C
Flag link:
Merck to take $2.9 billion charge on hepatitis C drug
Merck to take $2.9 billion charge on hepatitis C drug
Marketwatch
Merck
hepatitis C
uprifosbuvir
Flag link: